The 2026 awards ceremony holds particular weight as it coincides with the 20th anniversary of the Prix Galien USA edition. According to Kenneth C. Frazier and Dr. Michael Rosenblatt, co-chairs of the U.S. Awards Committee, the selection reflects a high degree of collaborative innovation across the global industry. The judging process is led by an international committee comprised of chairs from the foundation’s chapters worldwide, ensuring that the recognition spans contributions from across Africa, the Americas, Asia, and Europe.

The nominations feature a diverse array of industry leaders and emerging firms. Among the notable contenders in the biotechnology and pharmaceutical sectors are Roche’s Glofitamab, AstraZeneca’s Tagrisso, and Pfizer’s PAXLOVID. The medical technology category highlights advancements such as the Butterfly iQ3 portable ultrasound and the Omnipod 5 automated insulin delivery system. In the digital health space, nominees include the AI-Immunology platform from Evaxion and the Medable Agentic Clinical Development Platform. The startup category features firms like Dren Bio and PENTAVERE, emphasizing the foundation’s focus on the next generation of medical development. These awards, often described as the industry’s equivalent to the Nobel Prize, continue to function as a key barometer for progress in global health and biopharmaceutical research.